Abstract 5655
Background
Napabucasin (2-acetylfuro-1,4-naphthoquinone) is a small molecule currently being clinically evaluated in several different cancer types. It has mostly been recognized for its ability to inhibit STAT3-mediated gene expression with activity against bulk tumor cells, as well as cancer stem cells. However, based on its chemical structure, we hypothesized that napabucasin is a substrate for reduction by NAD(P)H:quinone oxidoreductase-1 (NQO1) and therefore may exert its anti-cancer effect through redox cycling, resulting in reactive oxygen species (ROS) production and cell death.
Methods
Binding of napabucasin to NQO1, as well as other oxidoreductases, was measured. Pancreatic cancer cell lines and xenografts were treated with napabucasin, and cell survival, ROS generation, glutathione to glutathione disulfide (GSH:GSSG) ratios and changes in STAT3 signaling were assayed. Genetic knockout or pharmacological inhibition with dicoumarol was used to evaluate the dependency on NQO1 in vitro and in vivo.
Results
Napabucasin was found to bind with high affinity to NQO1 and to a lesser degree to cytochrome P450 oxidoreductase (POR). Differential cytotoxic effects were observed, where NQO1-expressing cells in particular were highly sensitive. Treatment resulted in significant induction of ROS with reduced GSH:GSSG ratios, increased DNA damage and an NQO1-dependent decrease in STAT3 phosphorylation. Cells with low or no baseline NQO1 expression also produced ROS in response to napabucasin treatment, albeit to a lesser degree, through the one-electron reductase POR.
Conclusions
Napabucasin is bioactivated by oxidoreductases, in particular NQO1 and to a lesser extent POR, resulting in futile redox cycling and generation of cytotoxic levels of ROS. The increase in ROS has multiple intracellular effects, one of which is a reduction in STAT3 signaling, ultimately resulting in cell death.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Lustgarten Foundation, National Institutes of Health, Donaldson Charitable Trust, Boston Biomedical Inc.
Disclosure
J. Li: Full / Part-time employment: Boston Biomedical, Inc. A. Chang: Full / Part-time employment: Boston Biomedical, Inc.. H.A. Rogoff: Full / Part-time employment: Boston Biomedical, Inc.. J.D. Watson: Advisory / Consultancy, The consultancy occured in the past: Boston Biomedical, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract